Pirfenidone for idiopathic pulmonary fibrosis (CAPACITY trials, Lancet) - PulmCCM
Advertisement
Dec 262011
 

Noble et al report results of two Phase III placebo-controlled trials in N. America and Europe, with 779 patients total. In one trial, pirfenidone reduced FVC decline by ~4% at 72 weeks; in the other, it did not; pooling all the data, pirfenidone reduced FVC decline by 2.5% compared to placebo. There were abundant mild side effects in the treated arms (GI, photosensitivity and rash). Authors conclude the drug is “an appropriate treatment option” in IPF patients, but the FDA disagreed. (n=779) Lancet 2011;377:1760-1769.

In an earlier trial in Japan of 275 patients with IPF, pirfenidone reduced FVC decline by 70 mL and improved progression-free survival, resulting in its approval there. The FDA has indicated it will not approve pirfenidone for U.S. use without another clinical trial. InterMune, pirfenidone’s manufacturer, launched the phase 3 ASCEND trial in mid-2011 in response.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of pulmonary and critical care guidelines, practice updates and review articles.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society and/or journal referenced on the website.

  2 Responses to “Pirfenidone for idiopathic pulmonary fibrosis (CAPACITY trials, Lancet)”

  1. Last gasps from InterMune.

  2. I have used Pirfenidone on my patients with IPF with symptomatic benefit along with FVC and 6-MWD improvement. It seems to be a reasonable option in disease with limited treatment options!

Leave a Comment